Integrated clinical and basic studies related to circumventing non-small cell lung cancer drug resistance.
暂无分享,去创建一个
B. Kramer | J. Minna | A. Gazdar | H. Pass | J. Mulshine | T. Mitsudomi | B. Johnson | D. Ihde | B. Ghosh | R. Linnoila | R. Phelps | G. Shaw | B. Kramer
[1] S. Steinberg,et al. Individualized chemotherapy for patients with non-small cell lung cancer determined by prospective identification of neuroendocrine markers and in vitro drug sensitivity testing. , 1993, Cancer research.
[2] E. Holmes. Postoperative chemotherapy for non-small-cell lung cancer. , 1993, Chest.
[3] S. Steinberg,et al. Peripheral airway cell marker expression in non-small cell lung carcinoma. Association with distinct clinicopathologic features. , 1992, American journal of clinical pathology.
[4] G. Giaccone,et al. Association between histological type and neuroendocrine differentiation on drug sensitivity of lung cancer cell lines. , 1992, Journal of the National Cancer Institute. Monographs.
[5] S. Steinberg,et al. p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. , 1992, Oncogene.
[6] H. Garewal,et al. UC Irvine UC Irvine Previously Published Works Title Retinoids and carotenoids in the prevention of oral cancer : a critical appraisal , 2005 .
[7] M. Fukuoka,et al. Establishment of tumor cell lines as an independent prognostic factor for survival time in patients with small-cell lung cancer. , 1991, Journal of the National Cancer Institute.
[8] S. Steinberg,et al. ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. , 1991, Cancer research.
[9] J. Levy,et al. Photodynamic killing of human squamous cell carcinoma cells using a monoclonal antibody-photosensitizer conjugate. , 1991, Journal of the National Cancer Institute.
[10] J. Minna,et al. Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines. , 1991, Oncogene.
[11] S. Steinberg,et al. Nonrandom structural and numerical chromosome changes in non‐small‐cell lung cancer , 1991, Genes, chromosomes & cancer.
[12] J. Mulshine,et al. Lung cancer: rational strategies for early detection and intervention. , 1991, Oncology.
[13] J. Roth,et al. Photodynamic therapy of oncogene-transformed cells. , 1991, The Journal of thoracic and cardiovascular surgery.
[14] A. Gazdar,et al. Tumor cell lines established in vitro: an independent prognostic factor for survival in non-small-cell lung cancer. , 1990, Annals of internal medicine.
[15] L J Peters,et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. , 1990, The New England journal of medicine.
[16] G. Giaccone,et al. Reconstituted basement membrane (matrigel) and laminin can enhance the tumorigenicity and the drug resistance of small cell lung cancer cell lines. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[17] E. Dmitrovsky,et al. A Phase II Trial of Carboplatin (CBDCA) in Small‐Cell and Non‐Small‐Cell Lung Cancer with Correlation to In Vitro Analysis of Cytotoxicity , 1990, American journal of clinical oncology.
[18] C. Boone,et al. Identification of candidate cancer chemopreventive agents and their evaluation in animal models and human clinical trials: a review. , 1990, Cancer research.
[19] I. Pastan,et al. MDR1 gene expression in lung cancer. , 1989, Journal of the National Cancer Institute.
[20] S. Steinberg,et al. Lack of in vitro synergy between etoposide and cis-diamminedichloroplatinum(II). , 1989, Cancer research.
[21] S. Steinberg,et al. Neuroendocrine differentiation in endocrine and nonendocrine lung carcinomas. , 1988, American journal of clinical pathology.
[22] S. Rodenhuis,et al. Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. , 1988, Cancer research.
[23] A. Gazdar,et al. The pathology of lung cancer--changing concepts and newer diagnostic techniques. , 1988, Seminars in oncology.
[24] M. Sklar. Increased resistance to cis-diamminedichloroplatinum(II) in NIH 3T3 cells transformed by ras oncogenes. , 1988, Cancer research.
[25] S. Rodenhuis,et al. Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. , 1987, The New England journal of medicine.
[26] J. Mulshine,et al. Treatment of non-small-cell lung cancer. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] J. Battey,et al. Changes in the phenotype of human small cell lung cancer cell lines after transfection and expression of the c-myc proto-oncogene. , 1986, The Journal of clinical investigation.
[28] Griswold Dp. Body burden of cancer in relationship to therapeutic outcome: consideration of preclinical evidence. , 1986 .
[29] H. Kleinman,et al. Role of collagenous matrices in the adhesion and growth of cells , 1981, The Journal of cell biology.
[30] R C Young,et al. Combination versus single agent chemotherapy: A review of the basis for selection of drug treatment of cancer , 1975, Cancer.
[31] D. Slaughter,et al. “Field cancerization” in oral stratified squamous epithelium. Clinical implications of multicentric origin , 1953, Cancer.